Salbutamol Tablets

General Notices

Action and use

Beta2-adrenoceptor agonist; bronchodilator.

Definition

Salbutamol Tablets contain Salbutamol Sulfate.

The tablets comply with the requirements stated under Tablets and with the following requirements.

Content of salbutamol, C13H21NO3

92.5 to 107.5% of the stated amount.

Identification

A. Carry out the method described under Related substances applying separately to the plate 2 µL of each of the following solutions. For solution (1) shake a quantity of the powdered tablets containing the equivalent of 10 mg of salbutamol with 10 mL of methanol (80%) and filter. Solution (2) contains 0.12% w/v of salbutamol sulfate BPCRS. The principal spot in the chromatogram obtained with solution (1) corresponds to that in the chromatogram obtained with solution (2).
B. Shake a quantity of the powdered tablets containing the equivalent of 2.5 mg of salbutamol with 50 mL of a 2% w/v solution of sodium tetraborate, add 1 mL of a 3% w/v solution of 4-aminophenazone, 10 mL of a 2% w/v solution of potassium hexacyanoferrate(iii) and 10 mL of chloroform, shake and allow to separate. An orange-red colour is produced in the chloroform layer.
C. Shake a quantity of the powdered tablets containing the equivalent of 4 mg of salbutamol with 10 mL of water and filter. The filtrate yields the reactions characteristic of sulfates, Appendix VI.

Tests

Related substances

Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions.

(1) Shake a quantity of the tablets containing the equivalent of 48 mg of salbutamol with 60 mL of ethanol (50%) for 30 minutes, filter, evaporate to dryness using a rotary evaporator and gentle heat and dissolve the residue in 2 mL of water; if the residue is coloured, pass the final solution through a column (3 cm × 6 mm) packed with activated acid aluminium oxide (Brockmann Grade I is suitable).
(2) 0.058% w/v of salbutamol sulfate BPCRS in water.
(3) 0.022% w/v of salbutamol sulfate BPCRS in water.
chromatographic conditions
(a) Use as the coating silica gel G.
(b) Use the mobile phase as described below.
(c) Apply 10 µL of each solution.
(d) Develop the plate to 18 cm.
(e) After removal of the plate, dry in air, spray with a 0.1% w/v solution of 3-methylbenzothiazolin-2-one hydrazone hydrochloride in methanol (90%) followed by a 2% w/v solution of potassium hexacyanoferrate(iii) in a mixture of 1 volume of 18m ammonia and 3 volumes of water and spray again with the solution of methylbenzothiazolinone hydrazone hydrochloride.
mobile phase

3 volumes of 13.5m ammonia, 18 volumes of water, 35 volumes of ethyl acetate, 45 volumes of propan-2-ol and 50 volumes of 4-methylpentan-2-one.

limits

Any secondary spot in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (2) (2%) and not more than one such spot is more intense than the spot in the chromatogram obtained with solution (3) (0.75%).

Uniformity of content

Tablets containing less than the equivalent of 2 mg and/or less than 2% w/w of salbutamol comply with the requirements stated under Tablets using the following method of analysis. Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

(1) Add 50 mL of water to one tablet, shake for 1 hour, add sufficient water to produce 100 mL, mix, centrifuge and use the supernatant liquid.
(2) 0.060% w/v of 2-tert-butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate BPCRS and 0.060% w/v of salbutamol sulfate BPCRS in the mobile phase.
(3) 0.0024% w/v of salbutamol sulfate BPCRS in water.
chromatographic conditions
(a) Use a stainless steel column (20 cm × 5 mm) packed with spherical particles of silica, 5 µm in diameter, the surface of which has been modified with chemically-bonded nitrile groups (Spherisorb CN is suitable).
(b) Use isocratic elution and the mobile phase described below.
(c) Use a flow rate of 2.0 mL per minute.
(d) Use an ambient column temperature.
(e) Use a detection wavelength of 276 nm.
(f) Inject 20 µL of each solution.
mobile phase

5 volumes of propan-2-ol, 30 volumes of 0.05m ammonium acetate and 65 volumes of water; adjust the pH of the mixture to 4.5 with glacial acetic acid.

system suitability

The test is not valid unless, in the chromatogram obtained with solution (2), the resolution between the two principal peaks is at least 1.5.

determination of content

Calculate the content of C13H21NO3 in each tablet using the declared content of C13H21NO3 in salbutamol sulfate BPCRS.

Assay

For tablets containing the equivalent of less than 2 mg and/or less than 2% w/w of salbutamol

Use the average of the individual results determined in the test for Uniformity of content.

For tablets containing the equivalent of 2 mg or more and 2% w/w or more of salbutamol

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

(1) Shake 10 tablets with 100 mL of water for 1 hour, add sufficient water to produce a solution containing the equivalent of 0.040% w/v of salbutamol, mix, centrifuge and use the supernatant liquid.
(2) 0.048% w/v of 2-tert-butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate BPCRS and 0.048% w/v of salbutamol sulfate BPCRS in methanol (10%).
(3) 0.048% w/v of salbutamol sulfate BPCRS in water.
chromatographic conditions

The chromatographic conditions described under Uniformity of content may be used.

system suitability

The test is not valid unless, in the chromatogram obtained with solution (2), the resolution between the two principal peaks is at least 1.5.

determination of content

Calculate the content of C13H21NO3 in the tablets using the declared content of C13H21NO3 in salbutamol sulfate BPCRS.

Labelling

The quantity of active ingredient is stated in terms of the equivalent amount of salbutamol.